Matches in Nanopublications for { ?s ?p "[To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_assertion description "[To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- NP848579.RA7k228pCNu-ft2NIH-cX4RmiE29_LE2X9EfvR1eBzfVU130_assertion description "[To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP848579.RA7k228pCNu-ft2NIH-cX4RmiE29_LE2X9EfvR1eBzfVU130_provenance.